Live intranasal influenza vaccine showed a trend towards benefit in laboratory-confirmed influenza (RR 0.49, 95% CI 0.21 to 1.17), and an inconclusive effect in systemic adverse events ( general malaise: RR 3.09, 95% CI 0.18 to 53.20; fever: RR 1.71; 95% CI 0.09 to 33.24. 58 , 74 Administration of high-dose influenza vaccine in the elderly significantly reduced laboratory-confirmed influenza (RR 0.76, 95% CI 0.64 to 0.90), all-cause hospitalization (RR 0.93, 95% CI 0.90 to 0.96), and serious adverse events (RR 0.92, 95% CI 0.87 to 0.98) compared to standard-dose influenza vaccine.
← all excerpts
Philippine Clinical Practice Guidelines for Periodic Health Examination: Immunization for Adults.
1
—
—